Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Income (Loss) per Share - Basic and Diluted (Details)

Net Income (Loss) per Share - Basic and Diluted (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average unvested restricted common stock that has been issued and is subject to forfeiture (in shares)	216,788	70,550
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	52,493,447	1,946,748
Common Stock Warrants, Excluding Pre-funded Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	50,955,291	1,653,202
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	664,070	211,578
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	0	70,550
Preferred Stock, as Converted into Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	381,832	52
Common Stock Reserved for Future Issuance
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	492,254	11,366